Ascendis Pharma A (ASND) Non-Current Deffered Revenue (2021 - 2025)

Ascendis Pharma A (ASND) has 5 years of Non-Current Deffered Revenue data on file, last reported at $1.3 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Deffered Revenue fell 75.53% year-over-year to $1.3 million; the trailing twelve-month figure through Dec 2025 stood at $1.3 million (down 75.53% YoY), and the FY2025 full-year result was $1.3 million, down 75.84% from the prior year.
• Non-Current Deffered Revenue fell to $1.3 million in Q4 2025, from $5.3 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $14.5 million in Q4 2022 to a low of $1.3 million in Q4 2025.
• A 5-year average of $6.2 million and a median of $5.3 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue soared 327.66% in 2022 and sank 75.53% in 2025, its largest moves.
• Tracing ASND's Non-Current Deffered Revenue over 5 years: stood at $3.4 million in 2021, then soared by 327.66% to $14.5 million in 2022, then tumbled by 55.86% to $6.4 million in 2023, then declined by 16.53% to $5.3 million in 2024, then slumped by 75.53% to $1.3 million in 2025.
• Business Quant data shows ASND's Non-Current Deffered Revenue at $1.3 million in Q4 2025, $5.3 million in Q4 2024, and $6.4 million in Q4 2023.